Maintenance of Platelet Inhibition With Cangrelor

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Medicines Company
• Treatments: Cangrelor

Criteria

Inclusion Criteria:

• Written informed consent

• 18 Years of Age

• Non emergent coronary bypass graft surgery

• Received a thienopyridine within 48 hours prior to enrollment

Exclusion Criteria:

• Confirmed or suspected pregnancy

• Cerebrovascular accident within one yar

• Intracranial neoplasm

• History of bleeding diathesis

• Thrombocytopenia